Exjade Gains Approval in EU

Publication
Article
Oncology NEWS InternationalOncology NEWS International Vol 15 No 9
Volume 15
Issue 9

The European Commission (EC) has granted approval for Novartis' Exjade (deferasirox) to treat patients with transfusional iron overload in all 25 member states of the European Union (EU). Exjade, available in the United States, is an oral iron chelator that provides continuous chelation coverage with a single daily dose.

BASEL, Switzerland—The European Commission (EC) has granted approval for Novartis' Exjade (deferasirox) to treat patients with transfusional iron overload in all 25 member states of the European Union (EU). Exjade, available in the United States, is an oral iron chelator that provides continuous chelation coverage with a single daily dose.

Articles in this issue
Exjade Gains Approval in EU
Study Questions the Need for Maintenance Therapy in Metastatic Colorectal Cancer
President's Cancer Panel Assesses Progress in Two Areas
Proposed Medicare OPPS Rule Draws Fire for Its 'Inadequate Reimbursement'
Cognitive Rx Reduces Depression in Breast Ca Pts
Nurses Develop Evidence-Based Guidelines for Mucositis
Anastrozole Therapy for Breast Cancer Affects Bone Health
Is Demand for Trial Subjects Outpacing Supply?
Postchemo Disappearance of Liver Mets Doesn't Mean Cure
Aromasin-Related Bone Loss Affected by Vitamin D Levels
Melanoma Mets Regress After Gene Therapy
Phase I/II Trial of AGS-003
Short Course of Preoperative Radiotherapy Improves Outcomes in Patients With Resectable Rectal Cancer
President Bush Names Niederhuber NCI Director
Lack of EGFR Expression in Colon Ca Can Be Misleading
Recent Videos
Acupuncture
Related Content
Complete responses were numerically higher without significance in standard triple antiemetic therapy with olanzapine vs placebo.

Adding Olanzapine to Antiemetic Therapy May Help With CINV Incidence

Roman Fabbricatore
August 4th 2024
Article

Complete responses were numerically higher without significance in standard triple antiemetic therapy with olanzapine vs placebo.

Margaret Rosenzweig, PhD, CRNP-C, AOCNP, FAAN, discusses how nursling-led palliative care may improve advanced cancer care planning uptake based on a secondary analysis of the CONNECT study.

Oncology On-The-Go Podcast: Nursing-Led Palliative Care in Advanced Cancer

Margaret Rosenzweig, PhD, CRNP-C, AOCNP, FAAN
May 15th 2023
Podcast

Margaret Rosenzweig, PhD, CRNP-C, AOCNP, FAAN, discusses how nursling-led palliative care may improve advanced cancer care planning uptake based on a secondary analysis of the CONNECT study.

Incorporating nursing-led palliative care may help to improve advanced care planning among those with advanced cancer, especially those without access to specialty palliative care.

Nursing-Led Palliative Cancer Care May Improve Advanced Care Planning

Hayley Virgil
April 13th 2023
Article

Incorporating nursing-led palliative care may help to improve advanced care planning among those with advanced cancer, especially those without access to specialty palliative care.

Oncology Peer Review On-The-Go: Cancer-Related Fatigue Outcome Measures in Integrative Oncology

Oncology Peer Review On-The-Go: Cancer-Related Fatigue Outcome Measures in Integrative Oncology

Dori Beeler, PhD;Xin Shelley Wang, MD, MPH;Viraj A. Master, MD, PhD
September 20th 2022
Podcast

Authors Dori Beeler, PhD; Shelley Wang, MD, MPH; and Viraj A. Master, MD, PhD, spoke with CancerNetwork® about a review article on cancer-related fatigue published in the journal ONCOLOGY®.

Initial Data on Palliative 177Lu-FAP-2286 Highlights High Uptake and Prolonged Retention Across Several Adenocarcinomas

Initial Data on Palliative 177Lu-FAP-2286 Highlights High Uptake and Prolonged Retention Across Several Adenocarcinomas

Matthew Fowler
August 24th 2021
Article

Positive preliminary data on FAP-2286 linked to the radionuclide lutetium-177 across a diverse array of adenocarcinomas was reported from the phase 1/2 LuMIERE trial.

Qualitative Study Shares Strategies for Successful End of Life Conversations for Patients With Cancer

Qualitative Study Shares Strategies for Successful End of Life Conversations for Patients With Cancer

Ariana Pelosci
August 6th 2021
Article

Trends towards missing key moments for end-of-life discussions when meeting with patients who have stage IV cancer can be overcome with existing strategies for successful EOL conversations.